BioAlliance Expands LoramycTM Franchise by Signing a South East Asia Deal Worth up to $12M

Published: Mar 31, 2008

Paris, March 31th, 2008 – BioAlliance Pharma SA (Euronext Paris –BIO) today announced that it has entered into an exclusive licensing agreement under which Korea-based Handok Pharmaceuticals will receive commercialization rights in Korea, Taiwan, Singapore and Malaysia. BioAlliance Pharma’s innovative, muco-adhesive antifungal therapy Loramyc™ (miconazole Lauriad®) is already approved in Europe and a Phase III clinical trial has just completed in the United States.

BioAlliance Pharma’s third commercial partnership is potentially worth $12 million to the Paris-based firm, including $1.5 million on signature and a further $1.5 million on first sale in Korea - the remainder being sales milestones (up to $9 million) in the designated territory and double-digit royalties commensurate with the product stage.

Please, find below the English and French press releases, which are also available in PDF by clicking on the links at the end of this email.

Caroline Carmagnol ALIZE RP Tel.: +33 6 64 18 99 59 Hcaroline@alizerp.com

Back to news